ClinicalTrials.gg
CompletedNCT03075410Updated Apr 19, 2019Results posted

First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects

A Phase 1 interventional study of GSK3036656 and Placebo in Tuberculosis, sponsored by GlaxoSmithKline. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-19.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Tuberculosis by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Tuberculosis · GlaxoSmithKline.

Enrollment
16th of 21
30 · median 50
Started
2017
with 1 other
Phase 1
8 of 21
1 open now
Registered
15th of 21
by date

Among the 21 studies in Tuberculosis by GlaxoSmithKline, this one is the 16th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 1, and was the 15th registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

1 of the 21 studies in Tuberculosis by GlaxoSmithKline is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Tuberculosis by GlaxoSmithKline, or all of them as a file.
02

Study summary

GSK3036656 is being developed by GSK for the treatment of tuberculosis (TB). This is the FTIH study for GSK3036656 to evaluate the safety, tolerability and PK of single ascending and repeat oral doses of GSK3036656 in healthy adult subjects. The results of this study are intended to be used to identify appropriate and well-tolerated doses of GSK3036656 to be used in further studies. A food effect assessment will also be undertaken to investigate the influence of food on the PK of GSK3036656. The study will be conducted in two parts: Part A (single dose) and Part B (repeat dose). Up to two cohorts will be included in Part A. 9 healthy adult subjects will be included in each cohort. Each cohort will participate in up to 4 treatment (dosing) periods including a food effect treatment period. During each treatment period, GSK3036656 will be administered to 6 subjects and placebo will be administered to 3 subjects. The starting dose in Part A will be 5 milligrams (mg), and the maximum dose will be 1500 mg. The two cohorts in Part A will be dosed sequentially (i.e., dosing in Cohort 2 starts after dosing in Cohort 1 is completed). Initially, there will be a 14 day wash out period for individual subjects between each dose level. Study progression to Part B from Part A will be based on an acceptable safety, tolerability and PK profile in Part A. Part B will comprise up to 4 cohorts (Cohorts 3, 4, 5, and 6) each containing 10 (8 active: 2 placebo) healthy adult subjects to examine the safety, tolerability and PK of a repeated daily dose of GSK3036656 over a period of up to 14 days. Appropriate doses and dose regimens for Part B will be selected based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B. Dividing the total daily dose into 2 or 3 smaller doses may be done in both Part A and Part B. Up to 18 subjects will be enrolled into Part A and up to 40 subjects will be enrolled into Part B. The total duration of the study for each subject recruited into Part A and Part B will be approximately 12 weeks and 8 weeks, respectively.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • ascending dose
  • Pharmacokinetics
  • GSK3036656
  • FTIH
  • Safety
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 55 years of age inclusive, at the time of signing the .
  • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied, may be included only if the investigator in consultation with the medical monitor, if required, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Body weight >=60 kilograms (kg) and (BMI) within the range 19 to 29.9 kg/meter\^2 inclusive.
  • Male
  • Female subjects of non-child bearing potential are eligible to participate. Non-child bearing potential is defined as:

    • Pre-menopausal females with one of the following: documented tubal ligation; documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion or documented bilateral salpingectomy; hysterectomy; documented bilateral oophorectomy.
    • defined as 12 months of spontaneous amenorrhea. Post-menopausal status will be confirmed by a simultaneous follicle stimulating hormone (FSH) and estradiol levels test.
  • Male subjects with female partners of child bearing potential must comply with the following requirements from the time of first dose of study medication until 90 days after the last dose of study treatment (i.e. one sperm cycle).

    • Vasectomy with documentation of azoospermia.
    • Male condom plus partner use of one of the contraceptive options as follows: contraceptive subdermal implant; intrauterine device or intrauterine system; highly effective oral contraceptive, either combined or progestogen alone (provided it is associated with inhibition of ovulation); injectable progestogen; contraceptive vaginal ring; percutaneous contraceptive patches.
  • These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
  • The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion criteria

Exclusion criteria:

  • (ALT) and >1.5 times of (ULN) (isolated bilirubin >1.5 times of ULN may be acceptable, after consultation with the GlaxoSmithKline (GSK) medical monitor, if bilirubin is fractionated and direct bilirubin \<35 percent)
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • >450 milliseconds.
  • Presence of moderate or severe valve disorder or any other abnormality.
  • Subjects with a history of photosensitivity.
  • Females of non- who are susceptible to heavy periods or vaginal bleeding or spotting.
  • Pregnant females. A human chorionic gonadotrophin (hCG) test will be performed on Day -1 of each treatment (dosing) period in Part A and Part B for women for whom status has not been confirmed by FSH/estradiol testing. No pregnancy tests will be required for female subjects confirmed as post-menopausal by FSH/estradiol testing.
  • Lactating females.
  • Use of prescription or non-prescription drugs, including high-dose vitamins, herbal and dietary supplements (including Saint John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the investigator and sponsor, the medication will not interfere with the study procedures or compromise subject safety. Paracetamol for mild analgesia will be permitted.
  • Breath carbon monoxide test indicative of smoking or history of current use of tobacco- or nicotine-containing products.
  • Current regular alcohol consumption defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 milliliter [mL]) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
  • Subjects must not sunbathe or use a tanning device whilst taking the study medication and until at least 2 weeks after their last dose. Subjects are to be advised that they should wear protective clothing (e.g. sun hat, long sleeves) and use a broad spectrum ultraviolet A/ ultraviolet B sunscreen (sun protection factor >=30) when outdoors.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
  • Presence of surface antigen (HBsAg), positive antibody test result at screening or within 3 months prior to first dose of study treatment.
  • A positive test for (HIV) antibody.
  • A positive pre-study drug/alcohol screen.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1- GSK3036656 in Part A

    During Part A (Cohort 1), Subjects will receive a single dose of GSK3036656 in the morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. The total daily dose for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The starting dose in Part A will be 5 mg and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.

    Drug: GSK3036656

  • Placebo comparator
    Cohort 1- Placebo in Part A

    During Part A (Cohort 1), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. Placebo for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.

    Drug: Placebo

  • Experimental
    Cohort 2- GSK3036656 in Part A

    During Part A (Cohort 2), Subjects will receive a single dose of GSK3036656 in morning on Day 1 in each period after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. The total dose for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The dose will be selected on basis of safety, tolerability and PK data from the previous treatment period or cohort and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.

    Drug: GSK3036656

  • Placebo comparator
    Cohort 2- Placebo in Part A

    During Part A (Cohort 2), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. Placebo for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.

    Drug: Placebo

  • Experimental
    Cohort 3- GSK3036656 in Part B

    During Part B (Cohort 3), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from Part A. Subjects will be followed up to 2 weeks from the last dose.

    Drug: GSK3036656

  • Placebo comparator
    Cohort 3- Placebo in Part B

    During Part B (Cohort 3), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.

    Drug: Placebo

  • Experimental
    Cohort 4- GSK3036656 in Part B

    During Part B (Cohort 4), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.

    Drug: GSK3036656

  • Placebo comparator
    Cohort 4- Placebo in Part B

    During Part B (Cohort 4), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.

    Drug: Placebo

  • Experimental
    Cohort 5- GSK3036656 in Part B

    During Part B (Cohort 5), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.

    Drug: GSK3036656

  • Placebo comparator
    Cohort 5- Placebo in Part B

    During Part B (Cohort 5), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.

    Drug: Placebo

  • Experimental
    Cohort 6- GSK3036656 in Part B

    During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.

    Drug: GSK3036656

  • Placebo comparator
    Cohort 6- Placebo in Part B

    During Part B (Cohort 6), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.

    Drug: Placebo

Interventions

  • GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.

  • DrugPlacebo

    Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) for Part A

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above. Safety Population comprised of all randomized participants who received at least one dose of study medication.

    Time frame: Up to 12 weeks

  2. Number of Participants With nSAE and SAEs for Part B

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above.

    Time frame: Up to 8 weeks

  3. Number of Participants With Abnormal Electrocardiogram (ECG) Findings for Part A

    12-lead ECGs were collected during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) intervals. At each time point at which triplicate ECGs were required, three individual ECG tracings were obtained as closely as possible in succession, but no more than 2 to 5 minutes apart. ECG findings were categorized as normal, abnormal not clinically significant (A-NCS) and abnormal clinically significant (A-CS). Only A-NCS and A-CS worst case post-Baseline values have been presented. Only those participants with data available at the indicated time point were analyzed.

    Time frame: Up to 6 weeks

  4. Number of Subjects With Clinically Relevant Changes in ECG in Part B

    12-lead ECGs were collected during the study using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT interval and QTcF intervals. At each time point at which triplicate ECGs were required, three individual ECG tracings were obtained as closely as possible in succession, but no more than 2 to 5 minutes apart. ECG findings were categorized as normal, A-NCS and A-CS. Only A-NCS and A-CS worst case post-Baseline values have been presented.

    Time frame: Up to 8 weeks

  5. Number of Participants With Abnormal Cardiac Telemetry Findings for Part A

    Continuous cardiac telemetry was performed from approximately 1 hour pre-dose to 24 hours post dosing . Number of participants who had abnormal findings upon cardiac telemetry assessment have been presented.

    Time frame: 25 hours for each period

  6. Number of Participants With Abnormal Cardiac Telemetry Findings for Part B

    Continuous cardiac telemetry was performed from approximately 1 hour pre-dose to 24 hours post dosing . Number of participants who had abnormal findings upon cardiac telemetry assessment have been presented.

    Time frame: 25 hours for each period

  7. Number of Participants With Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) of Potential Clinical Importance (PCI) for Part A

    SBP and DBP were assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for SBP was less than 85 mmHg (lower) and greater than 160 mmHg (upper) while that for DBP was less than 45 mmHg (lower) and greater than 100 mmHg (upper).

    Time frame: Up to 6 weeks

  8. Number of Participants With Vital Sign Parameters SBP and DBP of PCI for Part B

    SBP and DBP were assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for SBP was less than 85 mmHg (lower) and greater than 160 mmHg (upper) while that for DBP was less than 45 mmHg (lower) and greater than 100 mmHg (upper).

    Time frame: Up to 8 weeks

  9. Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part A

    Heart rate was assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for heart was less than 40 bpm (lower) and greater than 110 bpm (upper).

    Time frame: Up to 6 weeks

  10. Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part B

    Heart rate was assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for heart was less than 40 bpm (lower) and greater than 110 bpm (upper).

    Time frame: Up to 8 weeks

  11. Number of Participants With Vital Sign Parameter Temperature of PCI for Part A

    Number of participants with temperature data of PCI have been presented.

    Time frame: Up to 6 weeks

  12. Number of Participants With Vital Sign Parameter Temperature of PCI for Part B

    Number of participants with temperature data of PCI have been presented.

    Time frame: Up to 8 weeks

  13. Number of Participants With Clinical Chemistry Parameters of PCI for Part A

    Blood samples were collected for the assessment of clinical chemistry parameters namely blood urea nitrogen (BUN), creatinine, glucose, cholesterol, potassium, sodium, calcium, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase, triglycerides, total and direct bilirubin, total protein, albumin and troponin. Only categories with PCI values have been presented, therefore only AST is presented.

    Time frame: Up to 12 weeks

  14. Number of Participants With Clinical Chemistry Parameters of PCI for Part B

    Blood samples were collected for the assessment of clinical chemistry parameters namely BUN, creatinine, glucose, cholesterol, potassium, sodium, calcium, AST, ALT, alkaline phosphatase, triglycerides, total and direct bilirubin, total protein, albumin and troponin. Only categories with PCI values have been presented.

    Time frame: Up to 8 weeks

  15. Number of Participants With Hematology Parameters of PCI for Part A

    Blood samples were collected for the assessment of hematology parameters platelet count, red blood cell count, hemoglobin, hematocrit, reticulocytes, mean corpuscle volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, basophils and eosinophils. Only categories with PCI values have been presented.

    Time frame: Up to 12 weeks

  16. Number of Participants With Hematology Parameters of PCI for Part B

    Blood samples were collected for the assessment of hematology parameters platelet count, red blood cell count, hemoglobin, hematocrit, reticulocytes, mean corpuscle volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, basophils and eosinophils. Only categories with PCI values have been presented.

    Time frame: Up to 8 weeks

  17. Number of Participants With Abnormal Urinalysis Parameters for Part A

    Urinalysis included dipstick urine test which was used to screen for glucose, ketones, occult blood and protein up to 72 hours post dose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, ketones, occult blood and protein can be read as negative, trace, trace-intact, trace-lysed,1+ and 2+ indicating proportional concentrations in the urine sample. Only categories with non-negative values have been presented. Only those participants with data available the indicated time points were analyzed.

    Time frame: Up to 72 hours post-dose

  18. Urine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part A

    Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 72 hours in Part A. Only those participants with data available at the indicated time points were analyzed.

    Time frame: Up to 72 hours post-dose

  19. Number of Participants With Abnormal Urinalysis Parameters for Part B

    Urinalysis included dipstick urine test which was used to screen for glucose, ketones, occult blood and protein up to 14 days post dose The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, ketones, occult blood and protein can be read as negative, trace, trace-intact, trace-lysed, 1+ and 2+ indicating proportional concentrations in the urine sample. Only categories with non-negative values have been presented. Only those participants available at the specified time points were analyzed represented by n=x in the category titles. Period 1 = Cohort 1 in Part B, Period 2 = Cohort 2 in Part B.

    Time frame: Up to 8 weeks

  20. Urine pH Analysis by Dipstick Method for Part B

    Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 8 weeks in Part B. Only those participants available at the specified time points were analyzed represented by n=x in the category titles. Period 1 = Cohort 1 in Part B, Period 2 = Cohort 2 in Part B.

    Time frame: Up to 8 weeks

  21. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) Following Single Dose Administration of GSK3036656 for Part A

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 Ethylenediaminetetraacetic acid (EDTA) tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. PK population comprised of participants in the Safety population who administered at least one dose of active treatment and had at least one evaluable PK sample.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  22. AUC From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3036656 Following Single Dose Administration for Part A

    Cmax will be derived from the PK samples collected at the indicated time points Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  23. Maximum Observed Plasma Drug Concentration (Cmax) of GSK3036656 Following Single Dose Administration for Part A

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  24. Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3036656 Following Single Dose Administration for Part A

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  25. Apparent Terminal Half-life (t1/2) of GSK3036656 Following Single Dose Administration for Part A

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  26. AUC[0-t] Following Repeated Dose Administration of GSK3036656 for Part B

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1. The actual date and time of each blood sample collection was recorded. Results presented are for Day 1.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1

  27. AUC From Time Zero During a Dosing Interval of Duration Tau (AUC[0-tau]) of GSK3036656 Following Repeated Dose Administration for Part B

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14The actual date and time of each blood sample collection was recorded. Results presented are for Day 14.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14

  28. Cmax of GSK3036656 Following Repeated Dose Administration for Part B

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. The actual date and time of each blood sample collection was recorded.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13

  29. Tmax of GSK3036656 Following Repeat Dose Administration for Part B

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. The actual date and time of each blood sample collection was recorded.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13

  30. t1/2 of GSK3036656 Following Repeated Dose Administration for Part B

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14. The actual date and time of each blood sample collection was recorded. Results presented are for Day 14.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14.

Secondary outcomes

  1. AUC (0-t) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  2. AUC (0-infinity) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  3. Cmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  4. t1/2 of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  5. Tmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

    Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  6. Observed Accumulation Ratio Based on AUC (AUC [Ro]) of GSK3036656 in Part B

    AUC Ro was calculated as Day 14 AUC(0-tau)/Day 1 AUC(0-t), where t and tau= 24 hours.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14

  7. Observed Accumulation Ratio Based on Cmax (RCmax) of GSK3036656 in Part B

    Rcmax was calculated as Day 14 Cmax/Day 1 Cmax. Statistics has been presented on geometric least square means.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14

  8. Steady State Ratio (Rss) of GSK3036656 in Part B

    Rss was calculated as Day 14 AUC (0-tau)/Day 1 AUC (0-inf). It was not possible to calculate AUC(0-inf) on Day 1 for the repeat dosing period, therefore it was not possible to calculate the (Rss).Na indicates data was not available.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14

  9. Trough Plasma Concentrations at the End of the Dosing Interval (Ctau) of GSK3036656 Following Repeat Dose Administrations in Part B

    Blood samples for the analysis of Ctau were collected at Day 1 (24 hours), Day 12 (Pre-dose ), Day 13 (Pre-dose ), Day 14 (Pre-dose), Day 14 (24 hours). Ctau samples collected were used to assess attainment of steady state. Statistics has been presented on geometric least square means.

    Time frame: Day 1 (24 hours), Day 12 (Pre-dose ), Day 13 (Pre-dose ), Day 14 (Pre-dose), Day 14 (24 hours)

  10. AUC (0-infinity) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A

    Blood samples for the analysis of AUC (0-infinity) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. AUC(0-infinity) following single doses was used for assessment of dose proportionality.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  11. AUC (0-t) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A

    Blood samples for the analysis of AUC (0-t) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. AUC(0-t) following single doses was used for assessment of dose proportionality.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  12. Cmax as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A

    Blood samples for the analysis of Cmax were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. Cmax following single doses was used for assessment of dose proportionality.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period

  13. AUC (0-tau) as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B

    Blood samples for the assessment of AUC (0-tau) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. AUC (0-tau) following repeat doses was used for assessment of dose proportionality.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13

  14. Cmax as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B

    Blood samples for the assessment of Cmax were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. Cmax following repeat doses was used for assessment of dose proportionality.

    Time frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13

07

Results

Posted Apr 19, 2019

Participant flow

This was a double blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of single and repeat doses of GSK3036656 in healthy adult participants. The study was conducted at 1 center in United Kingdom from 02-April-2017 to 04-August-2017. Part A was a crossover design, Part B was a parallel group design..

Part A-Period 1 (14 Days)
Participant flow — Part A-Period 1 (14 Days)
MilestonePartA - Placebo/15 mg/25 mg/5 mg (Fed)PartA - Placebo/15 mg/25 mg/PlaceboPartA - 5 mg/Placebo/25 mg/5 mg (Fed)PartA - 5 mg/Placebo/25 mg/PlaceboPartA - 5 mg/15 mg/Placebo/5 mg (Fed)PartA - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Started212121000
Completed212121000
Not completed000000000
Part A-Washout Period 1 (14 Days)
Participant flow — Part A-Washout Period 1 (14 Days)
MilestonePartA - Placebo/15 mg/25 mg/5 mg (Fed)PartA - Placebo/15 mg/25 mg/PlaceboPartA - 5 mg/Placebo/25 mg/5 mg (Fed)PartA - 5 mg/Placebo/25 mg/PlaceboPartA - 5 mg/15 mg/Placebo/5 mg (Fed)PartA - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Started212121000
Completed212121000
Not completed000000000
Part A-Period 2 (14 Days)
Participant flow — Part A-Period 2 (14 Days)
MilestonePartA - Placebo/15 mg/25 mg/5 mg (Fed)PartA - Placebo/15 mg/25 mg/PlaceboPartA - 5 mg/Placebo/25 mg/5 mg (Fed)PartA - 5 mg/Placebo/25 mg/PlaceboPartA - 5 mg/15 mg/Placebo/5 mg (Fed)PartA - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Started212121000
Completed111121000
Not completed101000000
Withdrew: Personal reasons101000000
Part A-Washout Period 2 (14 Days)
Participant flow — Part A-Washout Period 2 (14 Days)
MilestonePartA - Placebo/15 mg/25 mg/5 mg (Fed)PartA - Placebo/15 mg/25 mg/PlaceboPartA - 5 mg/Placebo/25 mg/5 mg (Fed)PartA - 5 mg/Placebo/25 mg/PlaceboPartA - 5 mg/15 mg/Placebo/5 mg (Fed)PartA - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Started111121000
Completed111121000
Not completed000000000
Part A-Period 3 (14 Days)
Participant flow — Part A-Period 3 (14 Days)
MilestonePartA - Placebo/15 mg/25 mg/5 mg (Fed)PartA - Placebo/15 mg/25 mg/PlaceboPartA - 5 mg/Placebo/25 mg/5 mg (Fed)PartA - 5 mg/Placebo/25 mg/PlaceboPartA - 5 mg/15 mg/Placebo/5 mg (Fed)PartA - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Started212121000
Completed112121000
Not completed100000000
Withdrew: Reaction to ecg tabs causing a rash100000000
Part A-Washout Period 3 (14 Days)
Participant flow — Part A-Washout Period 3 (14 Days)
MilestonePartA - Placebo/15 mg/25 mg/5 mg (Fed)PartA - Placebo/15 mg/25 mg/PlaceboPartA - 5 mg/Placebo/25 mg/5 mg (Fed)PartA - 5 mg/Placebo/25 mg/PlaceboPartA - 5 mg/15 mg/Placebo/5 mg (Fed)PartA - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Started112121000
Completed112121000
Not completed000000000
Part A-Period 4 (14 Days)
Participant flow — Part A-Period 4 (14 Days)
MilestonePartA - Placebo/15 mg/25 mg/5 mg (Fed)PartA - Placebo/15 mg/25 mg/PlaceboPartA - 5 mg/Placebo/25 mg/5 mg (Fed)PartA - 5 mg/Placebo/25 mg/PlaceboPartA - 5 mg/15 mg/Placebo/5 mg (Fed)PartA - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Started112121000
Completed112121000
Not completed000000000
Part B (up to 28 Days)
Participant flow — Part B (up to 28 Days)
MilestonePartA - Placebo/15 mg/25 mg/5 mg (Fed)PartA - Placebo/15 mg/25 mg/PlaceboPartA - 5 mg/Placebo/25 mg/5 mg (Fed)PartA - 5 mg/Placebo/25 mg/PlaceboPartA - 5 mg/15 mg/Placebo/5 mg (Fed)PartA - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Started000000478
Completed000000478
Not completed000000000

Outcome measures

PrimaryNumber of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) for Part A

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above. Safety Population comprised of all randomized participants who received at least one dose of study medication.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) for Part A
ParticipantsPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
nSAE11131
SAE00000
PrimaryNumber of Participants With nSAE and SAEs for Part B

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above.

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants With nSAE and SAEs for Part B
ParticipantsPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
nSAE021
SAE000
PrimaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings for Part A

12-lead ECGs were collected during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) intervals. At each time point at which triplicate ECGs were required, three individual ECG tracings were obtained as closely as possible in succession, but no more than 2 to 5 minutes apart. ECG findings were categorized as normal, abnormal not clinically significant (A-NCS) and abnormal clinically significant (A-CS). Only A-NCS and A-CS worst case post-Baseline values have been presented. Only those participants with data available at the indicated time point were analyzed.

Time frame:
Up to 6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings for Part A
ParticipantsPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
A-NCS21000
A-CS00000
PrimaryNumber of Subjects With Clinically Relevant Changes in ECG in Part B

12-lead ECGs were collected during the study using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT interval and QTcF intervals. At each time point at which triplicate ECGs were required, three individual ECG tracings were obtained as closely as possible in succession, but no more than 2 to 5 minutes apart. ECG findings were categorized as normal, A-NCS and A-CS. Only A-NCS and A-CS worst case post-Baseline values have been presented.

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Relevant Changes in ECG in Part B
ParticipantsPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
A-NCS133
A-CS000
PrimaryNumber of Participants With Abnormal Cardiac Telemetry Findings for Part A

Continuous cardiac telemetry was performed from approximately 1 hour pre-dose to 24 hours post dosing . Number of participants who had abnormal findings upon cardiac telemetry assessment have been presented.

Time frame:
25 hours for each period
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Cardiac Telemetry Findings for Part A
ParticipantsPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Number of Participants With Abnormal Cardiac Telemetry Findings for Part A00000
PrimaryNumber of Participants With Abnormal Cardiac Telemetry Findings for Part B

Continuous cardiac telemetry was performed from approximately 1 hour pre-dose to 24 hours post dosing . Number of participants who had abnormal findings upon cardiac telemetry assessment have been presented.

Time frame:
25 hours for each period
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Cardiac Telemetry Findings for Part B
ParticipantsPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Number of Participants With Abnormal Cardiac Telemetry Findings for Part B000
PrimaryNumber of Participants With Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) of Potential Clinical Importance (PCI) for Part A

SBP and DBP were assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for SBP was less than 85 mmHg (lower) and greater than 160 mmHg (upper) while that for DBP was less than 45 mmHg (lower) and greater than 100 mmHg (upper).

Time frame:
Up to 6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) of Potential Clinical Importance (PCI) for Part A
ParticipantsPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
SBP00000
DBP00000
PrimaryNumber of Participants With Vital Sign Parameters SBP and DBP of PCI for Part B

SBP and DBP were assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for SBP was less than 85 mmHg (lower) and greater than 160 mmHg (upper) while that for DBP was less than 45 mmHg (lower) and greater than 100 mmHg (upper).

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Parameters SBP and DBP of PCI for Part B
ParticipantsPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
SBP000
DBP001
PrimaryNumber of Participants With Vital Sign Parameter Heart Rate of PCI for Part A

Heart rate was assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for heart was less than 40 bpm (lower) and greater than 110 bpm (upper).

Time frame:
Up to 6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part A
ParticipantsPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part A00000
PrimaryNumber of Participants With Vital Sign Parameter Heart Rate of PCI for Part B

Heart rate was assessed in supine position with a completely automated device. Measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). The PCI range for heart was less than 40 bpm (lower) and greater than 110 bpm (upper).

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part B
ParticipantsPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part B000
PrimaryNumber of Participants With Vital Sign Parameter Temperature of PCI for Part A

Number of participants with temperature data of PCI have been presented.

Time frame:
Up to 6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Parameter Temperature of PCI for Part A
ParticipantsPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Number of Participants With Vital Sign Parameter Temperature of PCI for Part A00000
PrimaryNumber of Participants With Vital Sign Parameter Temperature of PCI for Part B

Number of participants with temperature data of PCI have been presented.

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Parameter Temperature of PCI for Part B
ParticipantsPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Number of Participants With Vital Sign Parameter Temperature of PCI for Part B000
PrimaryNumber of Participants With Clinical Chemistry Parameters of PCI for Part A

Blood samples were collected for the assessment of clinical chemistry parameters namely blood urea nitrogen (BUN), creatinine, glucose, cholesterol, potassium, sodium, calcium, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase, triglycerides, total and direct bilirubin, total protein, albumin and troponin. Only categories with PCI values have been presented, therefore only AST is presented.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinical Chemistry Parameters of PCI for Part A
ParticipantsPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Number of Participants With Clinical Chemistry Parameters of PCI for Part A00001
PrimaryNumber of Participants With Clinical Chemistry Parameters of PCI for Part B

Blood samples were collected for the assessment of clinical chemistry parameters namely BUN, creatinine, glucose, cholesterol, potassium, sodium, calcium, AST, ALT, alkaline phosphatase, triglycerides, total and direct bilirubin, total protein, albumin and troponin. Only categories with PCI values have been presented.

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinical Chemistry Parameters of PCI for Part B
ParticipantsPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
ALT010
AST010
PrimaryNumber of Participants With Hematology Parameters of PCI for Part A

Blood samples were collected for the assessment of hematology parameters platelet count, red blood cell count, hemoglobin, hematocrit, reticulocytes, mean corpuscle volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, basophils and eosinophils. Only categories with PCI values have been presented.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Hematology Parameters of PCI for Part A
ParticipantsPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Number of Participants With Hematology Parameters of PCI for Part A00000
PrimaryNumber of Participants With Hematology Parameters of PCI for Part B

Blood samples were collected for the assessment of hematology parameters platelet count, red blood cell count, hemoglobin, hematocrit, reticulocytes, mean corpuscle volume, mean corpuscular hemoglobin, neutrophils, lymphocytes, monocytes, basophils and eosinophils. Only categories with PCI values have been presented.

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Hematology Parameters of PCI for Part B
ParticipantsPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Leukocytes010
Neutrophils011
PrimaryNumber of Participants With Abnormal Urinalysis Parameters for Part A

Urinalysis included dipstick urine test which was used to screen for glucose, ketones, occult blood and protein up to 72 hours post dose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, ketones, occult blood and protein can be read as negative, trace, trace-intact, trace-lysed,1+ and 2+ indicating proportional concentrations in the urine sample. Only categories with non-negative values have been presented. Only those participants with data available the indicated time points were analyzed.

Time frame:
Up to 72 hours post-dose
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Parameters for Part A
ParticipantsPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Day -1, Ketone, Trace10100
Day -1, Occult blood, 1+00001
Day -1, Occult blood, 2+00100
Day -1, Occult blood, trace-intact10000
Day -1, Occult blood, trace-lysed10000
Day -1, Protein, Trace10201
24 hours, Ketones, 2+10000
24 hours, Occult blood, 2+00100
24 hours, Occult blood, trace-intact10000
24 hours, Occult blood, trace-lysed10000
72 hours, Ketone, Trace00100
72 hours, Occult blood, 1+10100
72 hours, Occult blood, trace-intact00001
72 hours, Occult blood, trace-lysed00010
72 hours, Protein, Trace20000
PrimaryUrine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part A

Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 72 hours in Part A. Only those participants with data available at the indicated time points were analyzed.

Time frame:
Up to 72 hours post-dose
Reported as:
Mean · pH
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part A
pHPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
pH at Day -16.08 ± 0.4696.00 ± 0.5485.50 ± 0.5485.92 ± 0.4926.70 ± 1.483
pH at 24 hours6.04 ± 0.4986.50 ± 0.4475.83 ± 0.2586.08 ± 0.2046.80 ± 1.095
pH at 72 hours6.46 ± 0.7536.00 ± 1.0955.92 ± 0.4926.42 ± 0.6657.30 ± 0.671
PrimaryNumber of Participants With Abnormal Urinalysis Parameters for Part B

Urinalysis included dipstick urine test which was used to screen for glucose, ketones, occult blood and protein up to 14 days post dose The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, ketones, occult blood and protein can be read as negative, trace, trace-intact, trace-lysed, 1+ and 2+ indicating proportional concentrations in the urine sample. Only categories with non-negative values have been presented. Only those participants available at the specified time points were analyzed represented by n=x in the category titles. Period 1 = Cohort 1 in Part B, Period 2 = Cohort 2 in Part B.

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Parameters for Part B
ParticipantsPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Day -1, Ketones, Trace,n=2,7,001—
Day -1, Occult blood,Trace-intact,n=2,7,010—
Day 14, Ketones, Trace,n=2,7,001—
Day 14, protein, 1+,n=2,7,001—
Day -1,Occult blood,Trace-intact,n=2,0,81—2
Day 6,Occult blood,Trace-intact,n=2,0,80—1
Day 6,Occult blood,Trace-lysed,n=2,0,80—2
Day 10, Ketones, Trace,n=2,0,80—1
Day 14, Protein, 2+,n=2,0,80—1
Follow-up (week 8), Ketones, n=4,7,8001
Follow up (week 8), Occult blood, n=4,7,8101
Follow-up(week 8),Occult blood,Trace-lysed,n=4,7,8002
PrimaryUrine pH Analysis by Dipstick Method for Part B

Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Urine samples were collected for the measurement of urine pH by method up to 8 weeks in Part B. Only those participants available at the specified time points were analyzed represented by n=x in the category titles. Period 1 = Cohort 1 in Part B, Period 2 = Cohort 2 in Part B.

Time frame:
Up to 8 weeks
Reported as:
Mean · pH
Urine pH Analysis by Dipstick Method for Part B
pHPart B-Matching PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
pH, Period 1, Day -1, n=2, 7, 06.25 ± 0.3546.71 ± 0.906—
pH, Period 1, Day 4, n= 2, 7, 06.25 ± 0.3545.79 ± 0.393—
pH, Period 1, Day 6, n=2, 7, 06.25 ± 0.3546.43 ± 0.535—
pH, Period 1, Day 10, n=2, 7, 06.25 ± 0.3546.14 ± 0.244—
pH, Period 1, Day 14, n=2, 7, 06.75 ± 0.3547.00 ± 0.957—
pH, Period 2, Day -1, n=2, 0, 86.50 ± 0.707—6.81 ± 0.594
pH, Period 2, Day 4, n=2, 0, 85.50 ± 0.707—6.25 ± 0.378
pH, Period 2, Day 6, n=2, 0, 86.50 ± 0.000—6.69 ± 0.458
pH, Period 2, Day 10, n=2, 0, 86.00 ± 0.000—6.38 ± 0.354
pH, Period 2, Day 14, n=2, 0, 86.00 ± 0.000—6.38 ± 0.582
pH, Follow-up (week 8), n=4, 7, 86.63 ± 0.7506.29 ± 0.4886.88 ± 0.744
PrimaryArea Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) Following Single Dose Administration of GSK3036656 for Part A

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 Ethylenediaminetetraacetic acid (EDTA) tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. PK population comprised of participants in the Safety population who administered at least one dose of active treatment and had at least one evaluable PK sample.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Geometric mean · hour*nanograms/milliliter
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) Following Single Dose Administration of GSK3036656 for Part A
hour*nanograms/milliliterPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) Following Single Dose Administration of GSK3036656 for Part A771.0468 ± 26.03252.9152 ± 24.15686.4151 ± 11.4782.7766 ± 18.1
PrimaryAUC From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3036656 Following Single Dose Administration for Part A

Cmax will be derived from the PK samples collected at the indicated time points Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Geometric mean · hour*nanograms/milliliter
AUC From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3036656 Following Single Dose Administration for Part A
hour*nanograms/milliliterPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
AUC From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3036656 Following Single Dose Administration for Part A1404.5416 ± 29.93796.1488 ± 19.86557.7764 ± 13.81450.7468 ± 9.4
PrimaryMaximum Observed Plasma Drug Concentration (Cmax) of GSK3036656 Following Single Dose Administration for Part A

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Geometric mean · nanograms/milliliter
Maximum Observed Plasma Drug Concentration (Cmax) of GSK3036656 Following Single Dose Administration for Part A
nanograms/milliliterPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Maximum Observed Plasma Drug Concentration (Cmax) of GSK3036656 Following Single Dose Administration for Part A49.06 ± 30.5177.61 ± 23.1207.38 ± 18.547.37 ± 23.5
PrimaryTime to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3036656 Following Single Dose Administration for Part A

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Median · hours
Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3036656 Following Single Dose Administration for Part A
hoursPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3036656 Following Single Dose Administration for Part A1.250 (0.50 to 1.50)1.000 (0.50 to 2.00)0.875 (0.75 to 2.00)2.000 (1.00 to 4.00)
PrimaryApparent Terminal Half-life (t1/2) of GSK3036656 Following Single Dose Administration for Part A

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Median · hours
Apparent Terminal Half-life (t1/2) of GSK3036656 Following Single Dose Administration for Part A
hoursPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Apparent Terminal Half-life (t1/2) of GSK3036656 Following Single Dose Administration for Part A38.3230 (25.632 to 70.970)28.4128 (24.462 to 32.497)47.9680 (35.996 to 67.360)32.4248 (30.449 to 46.455)
PrimaryAUC[0-t] Following Repeated Dose Administration of GSK3036656 for Part B

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1. The actual date and time of each blood sample collection was recorded. Results presented are for Day 1.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1
Reported as:
Geometric mean · hour*nanograms/milliliter
AUC[0-t] Following Repeated Dose Administration of GSK3036656 for Part B
hour*nanograms/milliliterPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
AUC[0-t] Following Repeated Dose Administration of GSK3036656 for Part B485.5625 ± 12.31891.0416 ± 9.9
PrimaryAUC From Time Zero During a Dosing Interval of Duration Tau (AUC[0-tau]) of GSK3036656 Following Repeated Dose Administration for Part B

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14The actual date and time of each blood sample collection was recorded. Results presented are for Day 14.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14
Reported as:
Geometric mean · hour*nanograms/milliliter
AUC From Time Zero During a Dosing Interval of Duration Tau (AUC[0-tau]) of GSK3036656 Following Repeated Dose Administration for Part B
hour*nanograms/milliliterPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
AUC From Time Zero During a Dosing Interval of Duration Tau (AUC[0-tau]) of GSK3036656 Following Repeated Dose Administration for Part B1392.2221 ± 12.54461.2565 ± 23.7
PrimaryCmax of GSK3036656 Following Repeated Dose Administration for Part B

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. The actual date and time of each blood sample collection was recorded.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
Reported as:
Geometric mean · nanograms/milliliter
Cmax of GSK3036656 Following Repeated Dose Administration for Part B
nanograms/milliliterPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Day 148.40 ± 33.6178.79 ± 32.8
Day 1497.04 ± 19.8309.55 ± 20.2
PrimaryTmax of GSK3036656 Following Repeat Dose Administration for Part B

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. The actual date and time of each blood sample collection was recorded.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
Reported as:
Median · hours
Tmax of GSK3036656 Following Repeat Dose Administration for Part B
hoursPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Day 11.0000 (0.500 to 3.000)0.7500 (0.500 to 1.500)
Day 140.7500 (0.500 to 1.500)0.7500 (0.500 to 1.500)
Primaryt1/2 of GSK3036656 Following Repeated Dose Administration for Part B

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14. The actual date and time of each blood sample collection was recorded. Results presented are for Day 14.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14.
Reported as:
Median · hours
t1/2 of GSK3036656 Following Repeated Dose Administration for Part B
hoursPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
t1/2 of GSK3036656 Following Repeated Dose Administration for Part B40.1802 (30.843 to 66.636)34.5109 (24.758 to 54.625)
SecondaryAUC (0-t) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Geometric mean · hours*nanograms/milliliter
AUC (0-t) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
hours*nanograms/milliliterPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
AUC (0-t) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A771.0468 ± 26.03252.9152 ± 24.15686.4151 ± 11.4782.7766 ± 18.1
Statistical analysis
  • Part A-GSK3036656 5 mg vs Part A-GSK3036656 5 mg (Fed) · Ratio: 1.07 · 90% CI 0.87 to 1.34Mixed Effect Model has been used to assess Food Effect for the log transformed parameter AUC(0-t). Treatment in the fed/fasted state is fitted as Fixed Effect. Participant is fitted as Random Effect. Variance Components covariance structure is used.
SecondaryAUC (0-infinity) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Geometric mean · hours*nanograms/milliliter
AUC (0-infinity) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
hours*nanograms/milliliterPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
AUC (0-infinity) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A1404.5416 ± 29.93796.1488 ± 19.86557.7764 ± 13.81450.7468 ± 9.4
Statistical analysis
  • Part A-GSK3036656 5 mg vs Part A-GSK3036656 5 mg (Fed) · Ratio: 0.94 · 90% CI 0.71 to 1.26Mixed Effect Model has been used to assess Food Effect for the log transformed parameter AUC(0-inf). Treatment in the fed/fasted state is fitted as Fixed Effect. Participant is fitted as Random Effect. Variance Components covariance structure is use
SecondaryCmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Geometric mean · nanograms/milliliter
Cmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
nanograms/milliliterPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Cmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A49.06 ± 30.5177.61 ± 23.1207.38 ± 18.535.54 ± 23.5
Statistical analysis
  • Part A-GSK3036656 5 mg vs Part A-GSK3036656 5 mg (Fed) · Ratio: 0.97 · 90% CI 0.76 to 1.23Mixed Effect Model has been used to assess Food Effect for the log transformed parameter Cmax. Treatment in the fed/fasted state is fitted as Fixed Effect. Participant is fitted as Random Effect. Variance Components covariance structure is used.
Secondaryt1/2 of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Median · hours
t1/2 of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
hoursPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
t1/2 of GSK3036656 Following Single Dose Administration in Fed Condition in Part A38.3230 (25.632 to 70.970)28.4128 (24.462 to 32.497)47.9680 (35.996 to 67.360)32.4248 (30.449 to 46.455)
Statistical analysis
  • Part A-GSK3036656 5 mg vs Part A-GSK3036656 5 mg (Fed) · Ratio: 0.89 · 90% CI 0.64 to 1.23Fixed Effect Model has been used to assess Food Effect for the log transformed parameter t1/2 Treatment in the fed/fasted state is fitted as Fixed Effect.
SecondaryTmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A

Blood samples for plasma PK analysis of GSK3036656 was collected into K3 EDTA tubes at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. The actual date and time of each blood sample collection was recorded. For the food effect assessment, the selected dose was given with a high fat meal.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Median · hours
Tmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A
hoursPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Tmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A1.250 (0.50 to 1.50)1.000 (0.50 to 2.00)0.875 (0.75 to 2.00)2.000 (1.00 to 4.00)
Statistical analysis
  • Part A-GSK3036656 5 mg vs Part A-GSK3036656 5 mg (Fed) · Median difference (final values): 0.75 · 90% CI -0.50 to 2.50Hodges-Lehmann estimation is used to calculate the 90% confidence interval.
SecondaryObserved Accumulation Ratio Based on AUC (AUC [Ro]) of GSK3036656 in Part B

AUC Ro was calculated as Day 14 AUC(0-tau)/Day 1 AUC(0-t), where t and tau= 24 hours.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14
Reported as:
Geometric mean · Ratio of AUC
Observed Accumulation Ratio Based on AUC (AUC [Ro]) of GSK3036656 in Part B
Ratio of AUCPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Observed Accumulation Ratio Based on AUC (AUC [Ro]) of GSK3036656 in Part B2.8672 ± 9.12.3592 ± 21.6
SecondaryObserved Accumulation Ratio Based on Cmax (RCmax) of GSK3036656 in Part B

Rcmax was calculated as Day 14 Cmax/Day 1 Cmax. Statistics has been presented on geometric least square means.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14
Reported as:
Geometric mean · Ratio of Cmax
Observed Accumulation Ratio Based on Cmax (RCmax) of GSK3036656 in Part B
Ratio of CmaxPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Observed Accumulation Ratio Based on Cmax (RCmax) of GSK3036656 in Part B2.0052 ± 24.31.7313 ± 26.7
SecondarySteady State Ratio (Rss) of GSK3036656 in Part B

Rss was calculated as Day 14 AUC (0-tau)/Day 1 AUC (0-inf). It was not possible to calculate AUC(0-inf) on Day 1 for the repeat dosing period, therefore it was not possible to calculate the (Rss).Na indicates data was not available.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14
Reported as:
Geometric mean · Ratio of AUC
Steady State Ratio (Rss) of GSK3036656 in Part B
Ratio of AUCPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Steady State Ratio (Rss) of GSK3036656 in Part BNA ± NANA ± NA
SecondaryTrough Plasma Concentrations at the End of the Dosing Interval (Ctau) of GSK3036656 Following Repeat Dose Administrations in Part B

Blood samples for the analysis of Ctau were collected at Day 1 (24 hours), Day 12 (Pre-dose ), Day 13 (Pre-dose ), Day 14 (Pre-dose), Day 14 (24 hours). Ctau samples collected were used to assess attainment of steady state. Statistics has been presented on geometric least square means.

Time frame:
Day 1 (24 hours), Day 12 (Pre-dose ), Day 13 (Pre-dose ), Day 14 (Pre-dose), Day 14 (24 hours)
Reported as:
Geometric mean · nanograms/milliliter
Trough Plasma Concentrations at the End of the Dosing Interval (Ctau) of GSK3036656 Following Repeat Dose Administrations in Part B
nanograms/milliliterPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Day 1, 24 hours14.32 ± 10.857.69 ± 10.5
Day 12, Pre-dose38.31 ± 20.8139.14 ± 21.6
Day 13, Pre-dose41.78 ± 14.5131.77 ± 28.8
Day 14, Pre-dose43.66 ± 15.1139.54 ± 32.5
Day 14, 24 hours44.34 ± 14.8139.25 ± 28.2
Statistical analysis
  • Part B-Repeat GSK3036656 5 mg · Slope: 1.10 · 90% CI 1.09 to 1.10Mixed Effect Model has been used to assess Steady State. Day is fitted as a Fixed Effect. Participant is fitted as Random Effect Variance Components covariance structure is used.
  • Part B-Repeat GSK3036656 15 mg · Slope: 1.08 · 90% CI 1.07 to 1.08Mixed Effect Model has been used to assess Steady State. Day is fitted as a Fixed Effect. Participant is fitted as Random Effect Variance Components covariance structure is used.
SecondaryAUC (0-infinity) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A

Blood samples for the analysis of AUC (0-infinity) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. AUC(0-infinity) following single doses was used for assessment of dose proportionality.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Geometric mean · hours*nanograms/milliliter
AUC (0-infinity) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A
hours*nanograms/milliliterPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
AUC (0-infinity) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A1404.5416 ± 29.93796.1488 ± 19.86557.7764 ± 13.81450.7468 ± 9.4
Statistical analysis
  • Part A-GSK3036656 5 mg vs Part A-GSK3036656 15 mg · Slope: 0.96 · 90% CI 0.82 to 1.10A slope of 1 indicates the pharmacokinetics are dose proportional. A slope greater than 1 indicates the increase in PK is greater than proportional to dose.
SecondaryAUC (0-t) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A

Blood samples for the analysis of AUC (0-t) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. AUC(0-t) following single doses was used for assessment of dose proportionality.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Geometric mean · hours*nanograms/milliliter
AUC (0-t) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A
hours*nanograms/milliliterPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
AUC (0-t) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A771.0468 ± 26.03252.9152 ± 24.15686.4151 ± 11.4782.7766 ± 18.1
Statistical analysis
  • Part A-GSK3036656 5 mg vs Part A-GSK3036656 15 mg · Slope: 1.32 · 90% CI 1.24 to 1.39Power Model has been used to assess Dose Proportionality. Log-e(dose) is fitted as Fixed Effect and Participant is fitted as Random Effect. An Unstructured covariance structure is used.
SecondaryCmax as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A

Blood samples for the analysis of Cmax were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period. Cmax following single doses was used for assessment of dose proportionality.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
Reported as:
Geometric mean · hours*nanograms/milliliter
Cmax as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A
hours*nanograms/milliliterPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)
Cmax as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A49.06 ± 30.5177.61 ± 23.1207.38 ± 18.547.37 ± 23.5
Statistical analysis
  • Part A-GSK3036656 5 mg vs Part A-GSK3036656 15 mg · Slope: 0.96 · 90% CI 0.81 to 1.11Power Model has been used to assess Dose Proportionality. Log-e(dose) is fitted as Fixed Effect and Participant is fitted as Random Effect. An Unstructured covariance structure is used.
SecondaryAUC (0-tau) as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B

Blood samples for the assessment of AUC (0-tau) were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. AUC (0-tau) following repeat doses was used for assessment of dose proportionality.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
Reported as:
Geometric mean · hours*nanograms/milliliter
AUC (0-tau) as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B
hours*nanograms/milliliterPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
AUC (0-tau) as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B1392.2221 ± 12.54461.2565 ± 23.7
Statistical analysis
  • Part B-Repeat GSK3036656 5 mg vs Part B-Repeat GSK3036656 15 mg · Slope: 1.24 · 90% CI 1.15 to 1.33Day 1.Power Model has been used to assess Dose Proportionality. Log-e(dose) is fitted as Fixed Effect.
  • Part B-Repeat GSK3036656 5 mg vs Part B-Repeat GSK3036656 15 mg · Slope: 1.06 · 90% CI 0.90 to 1.22Day 14. Power Model has been used to assess Dose Proportionality. Log-e(dose) is fitted as Fixed Effect.
SecondaryCmax as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B

Blood samples for the assessment of Cmax were collected at Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13. Cmax following repeat doses was used for assessment of dose proportionality.

Time frame:
Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
Reported as:
Geometric mean · nanograms/milliliter
Cmax as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B
nanograms/milliliterPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mg
Day 148.40 ± 33.6178.79 ± 32.8
Day 1497.04 ± 19.8309.55 ± 20.2
Statistical analysis
  • Part B-Repeat GSK3036656 5 mg vs Part B-Repeat GSK3036656 15 mg · Slope: 1.19 · 90% CI 0.92 to 1.46Day 1. Power Model has been used to assess Dose Proportionality. Log-e(dose) is fitted as Fixed Effect.
  • Part B-Repeat GSK3036656 5 mg vs Part B-Repeat GSK3036656 15 mg · Slope: 1.06 · 90% CI 0.89 to 1.22Day 14. Power Model has been used to assess Dose Proportionality. Log-e(dose) is fitted as Fixed Effect.

Adverse events

Collected over nSAEs and SAEs were collected from Day -1 until 12 weeks in Part A and until 8 weeks in Part B.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A-Matching Placebo0/9 (0%)0/9 (0%)1/9 (11.1%)
Part A-GSK3036656 5 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A-GSK3036656 15 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A-GSK3036656 25 mg0/6 (0%)0/6 (0%)3/6 (50%)
Part A-GSK3036656 5 mg (Fed)0/5 (0%)0/5 (0%)1/5 (20%)
Part B-Matching Placebo0/4 (0%)0/4 (0%)0/4 (0%)
Part B-GSK3036656 5 mg0/7 (0%)0/7 (0%)2/7 (28.6%)
Part B-GSK3036656 15 mg0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPart A-Matching PlaceboPart A-GSK3036656 5 mgPart A-GSK3036656 15 mgPart A-GSK3036656 25 mgPart A-GSK3036656 5 mg (Fed)Part B-Matching PlaceboPart B-GSK3036656 5 mgPart B-GSK3036656 15 mg
Abdominal painGastrointestinal disorders0/90/60/62/60/50/40/70/8
HeadacheNervous system disorders0/90/61/61/60/50/42/70/8
CoughRespiratory, thoracic and mediastinal disorders0/90/60/60/61/50/40/70/8
EpistaxisRespiratory, thoracic and mediastinal disorders0/91/60/60/60/50/40/70/8
Medical device site dermatitisGeneral disorders0/90/60/61/60/50/40/70/8
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/90/60/61/60/50/40/70/8
DizzinessNervous system disorders0/90/60/60/60/50/41/70/8
Medical device site reactionGeneral disorders0/90/60/60/60/50/41/70/8
Infectious mononucleosisInfections and infestations0/90/60/60/60/50/41/70/8
Liver function test increasedInvestigations0/90/60/60/60/50/41/70/8

Baseline characteristics

9 participants were randomized at the beginning of Part A. During Part A, 2 of the 3 participants who withdrew were replaced, hence 11 randomized.

Age, Continuous
Age, Continuous(Years)Part A - Placebo/15 mg/25 mg/5 mg (Fed)Part A - Placebo/15 mg/25 mg/PlaceboPart A - 5 mg/Placebo/25 mg/5 mg (Fed)Part A - 5 mg/Placebo/25 mg/PlaceboPart A - 5 mg/15 mg/Placebo/5 mg (Fed)Part A - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mgTotal
Mean33.7 ± 5.0325 ± NA26.3 ± 2.5228.0 ± NA34.0 ± 1.4150.0 ± NA30.3 ± 9.4331.9 ± 6.2635.1 ± 7.8832.5 ± 7.39
Sex: Female, Male
Sex: Female, Male(Participants)Part A - Placebo/15 mg/25 mg/5 mg (Fed)Part A - Placebo/15 mg/25 mg/PlaceboPart A - 5 mg/Placebo/25 mg/5 mg (Fed)Part A - 5 mg/Placebo/25 mg/PlaceboPart A - 5 mg/15 mg/Placebo/5 mg (Fed)Part A - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mgTotal
Female0000010001
Male31312047829
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A - Placebo/15 mg/25 mg/5 mg (Fed)Part A - Placebo/15 mg/25 mg/PlaceboPart A - 5 mg/Placebo/25 mg/5 mg (Fed)Part A - 5 mg/Placebo/25 mg/PlaceboPart A - 5 mg/15 mg/Placebo/5 mg (Fed)Part A - 5 mg/15 mg/Placebo/PlaceboPart B-PlaceboPart B-Repeat GSK3036656 5 mgPart B-Repeat GSK3036656 15 mgTotal
American Indian/Alaskan Native1000000001
Asian-South Asian Heritage0000101002
Black/ African American1000000102
White-White/Caucasian/European Heritage11311125823
Unknown0000001102
08

Study locations

2 sites
  • GSK Investigational Site
    London, NW10 7EW, United Kingdom
  • GSK Investigational Site
    London, NW10 7, United Kingdom
09

References and documents

Publications

  • Tenero D, Derimanov G, Carlton A, Tonkyn J, Davies M, Cozens S, Gresham S, Gaudion A, Puri A, Muliaditan M, Rullas-Trincado J, Mendoza-Losana A, Skingsley A, Barros-Aguirre D. First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00240-19. doi: 10.1128/AAC.00240-19. Print 2019 Aug. PubMed 31182528 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Aug 2017, 4 months.

Results were first posted in Apr 2019, 1 year 8 months after primary completion.

Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2017
First posted
Mar 9, 2017
StartActual
Apr 2, 2017
Primary completionActual
Aug 4, 2017
CompletionActual
Aug 4, 2017
Results first posted
Apr 19, 2019
Last update
Apr 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03075410
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 9, 2017
Start date
Apr 2, 2017
Primary completion
Aug 4, 2017
Completion
Aug 4, 2017
Results posted
Apr 19, 2019
Last update
Apr 19, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
GSK Clinical Trials
study director · GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK656

Start the discussion